SecSonar.com

Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Recursion Pharmaceuticals, Inc. (RXRX) is a Biotechnology company based in US with a market capitalization of $1.6B. Revenue grew 26.9% year-over-year and free cash flow was negative at -$378.3M. This page tracks RXRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 800 employees · IPO Apr 16, 2021

Valuation

Valuation & price

$2.93 · as of May 17, 2026 · -56.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.41

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.49$4.69$2.89Jul 25Dec 25Jul 26Jul 7, 25$4.93Jul 9, 25$5.59Jul 11, 25$5.28Jul 15, 25$5.22Jul 17, 25$5.52Jul 21, 25$6.40Jul 23, 25$6.43Jul 25, 25$6.49Jul 29, 25$5.95Jul 31, 25$5.95Aug 4, 25$5.80Aug 6, 25$5.48Aug 11, 25$5.29Aug 13, 25$5.70Aug 15, 25$5.77Aug 19, 25$5.09Aug 21, 25$4.78Aug 25, 25$4.83Aug 27, 25$4.89Aug 29, 25$4.70Sep 3, 25$4.63Sep 5, 25$4.61Sep 9, 25$4.70Sep 11, 25$4.85Sep 16, 25$4.84Sep 18, 25$4.93Sep 22, 25$4.98Sep 24, 25$4.88Sep 26, 25$4.72Sep 30, 25$4.88Oct 2, 25$5.52Oct 6, 25$5.53Oct 8, 25$6.09Oct 10, 25$5.32Oct 14, 25$5.89Oct 16, 25$6.36Oct 21, 25$6.11Oct 23, 25$5.73Oct 27, 25$6.30Oct 29, 25$5.87Oct 31, 25$5.52Nov 4, 25$5.00Nov 6, 25$4.62Nov 10, 25$4.51Nov 12, 25$4.65Nov 14, 25$4.14Nov 18, 25$4.16Nov 20, 25$3.85Nov 25, 25$4.37Nov 28, 25$4.63Dec 2, 25$4.32Dec 4, 25$4.92Dec 8, 25$4.82Dec 10, 25$4.77Dec 12, 25$4.33Dec 16, 25$4.20Dec 18, 25$4.44Dec 22, 25$4.40Dec 24, 25$4.40Dec 29, 25$4.13Jan 2, 26$4.20Jan 6, 26$4.55Jan 8, 26$4.70Jan 12, 26$4.81Jan 14, 26$4.85Jan 16, 26$4.67Jan 21, 26$4.61Jan 23, 26$4.73Jan 27, 26$4.60Jan 29, 26$4.32Feb 2, 26$4.18Feb 4, 26$3.90Feb 9, 26$3.98Feb 11, 26$3.71Feb 13, 26$3.49Feb 18, 26$3.53Feb 20, 26$3.42Feb 24, 26$3.53Feb 26, 26$3.77Mar 2, 26$3.63Mar 4, 26$3.64Mar 6, 26$3.46Mar 10, 26$3.44Mar 12, 26$3.29Mar 17, 26$3.42Mar 19, 26$3.37Mar 23, 26$3.23Mar 25, 26$3.17Mar 27, 26$2.94Mar 31, 26$3.07Apr 2, 26$3.11Apr 7, 26$3.19Apr 9, 26$3.31Apr 13, 26$3.42Apr 15, 26$3.75Apr 17, 26$3.78Apr 22, 26$3.73Apr 24, 26$3.51Apr 28, 26$3.41Apr 30, 26$3.46May 4, 26$3.52May 6, 26$3.43May 8, 26$3.32May 12, 26$3.15May 14, 26$3.04May 18, 26$2.89May 20, 26$2.96May 22, 26$3.01May 28, 26$3.44Jun 1, 26$3.79Jun 3, 26$3.47Jun 5, 26$3.32Jun 9, 26$3.22Jun 11, 26$3.15Jun 15, 26$3.29Jun 17, 26$3.11Jun 22, 26$3.18Jun 24, 26$3.23Jun 26, 26$3.52Jul 2, 26$3.80
$2.8452-week range$6.79
Loading valuation history…

Fundamentals

Key fundamentals

$1.6B

Market cap

26.9%

Revenue growth (YoY)

-62.0%

Gross margin

-$378.3M

Free cash flow (USD)

-$665.3M

Net debt

Net cash position

63.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$1.7MFY 2020$3.4MFY 2021$10.0MFY 2022$39.7MFY 2023$43.9MFY 2024$58.8MFY 2025$74.7M
$1.7M$74.7M

Free cash flow by year

2019 → 2025

FY 2019$-61.0MFY 2020$-52.1MFY 2021$-198.4MFY 2022$-120.9MFY 2023$-299.7MFY 2024$-372.9MFY 2025$-378.3M
-$61M-$378.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022-21.7%FY 20232.9%FY 202423.1%FY 2025-62.0%
100.0%-62.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $13K · 10b5-1 PlanBumpus Namandje · Director · $12.6KJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventDirector DepartureApr 30, 2026Filing

Questions

Frequently asked questions

What is Recursion Pharmaceuticals, Inc.'s market cap?

Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalization of $1.6B.

What is RXRX's P/E ratio?

A meaningful P/E ratio is not available for RXRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is RXRX's price-to-book (P/B) ratio?

RXRX trades at 1.41 times book value per share.

Are insiders buying RXRX stock?

SEC Form 4 filings show no open-market insider buys at Recursion Pharmaceuticals, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

INVA

Innoviva, Inc.

$1.6B

NTLA

Intellia Therapeutics, Inc.

$1.6B

VIR

Vir Biotechnology, Inc.

$1.6B

VRDN

Viridian Therapeutics, Inc.

$1.6B

NRIX

Nurix Therapeutics, Inc.

$1.5B

NUVB

Nuvation Bio Inc.

$1.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.